vs
Side-by-side financial comparison of Biogen (BIIB) and Concord Medical Services Holdings Ltd (CCM). Click either name above to swap in a different company.
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for ...
Concord Medical Services Holdings Ltd is an integrated healthcare provider specializing in oncology care, radiotherapy, and medical diagnostic imaging services focused on the Chinese market. It operates a network of cancer treatment centers, partners with public and private medical institutions to deliver care, and offers medical equipment management solutions.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.6B | — | ||
| Q1 25 | $2.4B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.3B | — |
| Q4 25 | $-48.9M | — | ||
| Q3 25 | $466.5M | — | ||
| Q2 25 | $634.8M | — | ||
| Q1 25 | $240.5M | — | ||
| Q4 24 | $266.7M | — | ||
| Q3 24 | $388.5M | — | ||
| Q2 24 | $583.6M | — | ||
| Q1 24 | $393.4M | — |
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.3% | — |
| Q4 25 | -2.5% | — | ||
| Q3 25 | 22.0% | — | ||
| Q2 25 | 28.1% | — | ||
| Q1 25 | 12.8% | — | ||
| Q4 24 | 11.9% | — | ||
| Q3 24 | 18.3% | — | ||
| Q2 24 | 28.3% | — | ||
| Q1 24 | 20.3% | — |
| Q4 25 | -2.1% | — | ||
| Q3 25 | 18.4% | — | ||
| Q2 25 | 24.0% | — | ||
| Q1 25 | 9.9% | — | ||
| Q4 24 | 10.9% | — | ||
| Q3 24 | 15.8% | — | ||
| Q2 24 | 23.7% | — | ||
| Q1 24 | 17.2% | — |
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $3.17 | — | ||
| Q2 25 | $4.33 | — | ||
| Q1 25 | $1.64 | — | ||
| Q4 24 | $1.82 | — | ||
| Q3 24 | $2.66 | — | ||
| Q2 24 | $4.00 | — | ||
| Q1 24 | $2.70 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
